Onset CE marks heart valve delivery catheter
This article was originally published in Clinica
Executive Summary
Onset Medical has CE marked its SoloPath endovascular access catheter for sale in Europe. The catheter is designed to deliver devices such as heart valves via the femoral and iliac arteries into the larger aortic artery. Up to 20% of patients who require replacement aortic heart valves have severe atherosclerosis in their leg arteries, the Irvine, California firm claims, which may prevent the use of newer percutaneous aortic valves being marketed in Europe by Edwards Lifesciences and Medtronic. In these patients, the valve has to be delivered either through a minimally-invasive incision near the heart or via a totally open-heart surgical procedure. The SoloPath could provide access to these diseased arteries, allowing more patients to be treated with percutaneously implanted aortic heart valves. The SoloPath can also deliver stent grafts for the treatment of aortic aneurysms. Onset expects to launch the SoloPath during the fourth quarter.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?